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Introduction
Women infected with the human immunodeficiency virus (HIV) 
type 1 confront a dilemma when deciding whether or not to breast-
feed. In the absence of antiretroviral therapy it is estimated that there 
is a 14% risk of mother-to-child HIV transmission through prolonged 
breast-feeding.1 This must be balanced against the many benefits of 
breast-feeding, most importantly protection against infections and 
especially diarrhoeal diseases.2 
For women electing not to breast-feed, it is important to minimise 
the risks of formula feeding. Non-breast-fed infants are usually given 
a standard whey-adapted starter formula that is in many respects 
close to human milk. A biologically acidified starter formula has 
been widely used in South Africa, as there is some evidence that this 
inhibits the growth of pathogenic bacteria in vitro 3,4,5 and reduces 
the incidence of diarrhoea in infants.6,7
The protection breast-feeding affords against diarrhoeal disease may, 
in part, relate to the characteristics of the intestinal micro-flora, which 
acts as a protective barrier against colonisation with pathogens, and 
also promotes certain gut immune functions.8 In breast-fed infants, 
bifidobacteria are the predominant anaerobic bacteria in the faecal 
micro-flora,9,10 whereas in infants receiving standard milk formula 
the dominant species also include enterobacteria, enterococci and 
bacteroides.11 Modulation of the microbial flora towards increased 
bifidobacteria counts has been successfully achieved by adding 
either living bifidobacteria (probiotics) or substances enhancing 
the growth of specific bacteria (prebiotics), or both (synbiotics) to 
infant feeds.  
Some evidence exists that the use of infant milk formula that is 
biologically acidified and contains bifidobacteria is associated with 
normal growth in early infancy,12 and it is possible that such infant 
formulas could increase infant growth, either by reducing infections 
or through other mechanisms. Previous controlled trials of the use 
of probiotics or prebiotics in infants have demonstrated increased 
infant growth in some studies but not others.14, 15
Objectives 
The primary objective of this study was to compare growth rates of 
HIV-exposed, uninfected infants fed a biologically acidified starter 
Abstract
Objectives: To compare the growth of HIV-exposed uninfected infants fed a biologically acidified milk formula with or without 
probiotics (Bifidobacterium lactis) during the first six months of life, with control infants fed a standard starter formula. 
Design: Multi-centre, double-blinded randomised controlled trial. 
Setting: Infants born to HIV-infected women delivering at one of three academic hospitals in Johannesburg, South Africa. 
Subjects: Consenting HIV-positive women, who had previously decided not to breast-feed, were randomised to receive one of three 
milk formulas for their newborn infants. 
Outcome measures: Comparisons of growth parameters through the first four months of life were made between infants fed the 
acidified formula without probiotics and those fed the control formula (“acidification effect”), and between infants fed the acidified 
formulas with and without added probiotics (“probiotic effect”).    
Results: Of 131 randomised infants, 33 (25%) did not complete the study and 13 (10%) were HIV infected, leaving 85 infants available 
for analysis. Infants receiving the acidified formula with probiotics had more rapid head growth (p=0.04) and showed a trend towards 
more rapid weight gain (p=0.06) over the first four months of life than the infants receiving the acidified formula without probiotics. 
No other significant differences between the feeding groups were demonstrated.
Conclusions: Infants in all study groups grew well, with increased head growth and a trend towards increased weight gain for those 
receiving probiotics. There were no differences in morbidity between the three study groups and no evidence of adverse effects of 
the study formulas.
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formula with or without probiotics, with growth rates of infants fed 
a standard non-acidified starter formula. The primary outcome was 
weight gain (g/d) defined as the increment of weight divided by 
the increment of age between enrolment and the visit at day 119. 
Day 119 corresponded to four months of age and this was chosen 
as the end point for the primary objective as foods other than milk 
were introduced after that age. Secondary objectives were to assess 
tolerance of acidified formulas with and without probiotics and to 
evaluate the frequency of episodes of intercurrent infections.
Methods
This study was a multi-centre, double-blinded randomised controlled 
trial conducted at three teaching hospitals of the University of the 
Witwatersrand, Johannesburg, namely the Chris Hani-Baragwanath, 
Coronation and Johannesburg hospitals.
The study was approved by the Committee for Research on Human 
Subjects of the University of the Witwatersrand and all mothers of 
infants enrolled gave written informed consent. 
As part of antenatal care, pregnant women attending the antenatal 
clinics of all three hospitals were routinely offered HIV testing. 
Those who tested positive received full post-test counselling, which 
included discussion of infant feeding options. Women who decided 
against breast-feeding were informed about the study, but enrolment 
only took place after delivery.  
Inclusion criteria were normally grown (birth weight 2500– 
4200 g), term (gestation 37–42 weeks) male or female infants born 
to HIV-infected women who had elected not to breast-feed. Infants 
were excluded if they had major congenital abnormalities or major 
illness requiring either admission to an intensive care unit or hospital 
admission for more than three days. Subjects were also excluded if 
the mother planned to introduce other feeds in the first four months 
of life, or planned to move out of the area during the six-month study 
period. Recruitment was within one week of birth.
After enrolment, infants were assigned to one of three groups:
1. A whey-adapted starter formula (control group)
2. A biologically acidified whey-adapted starter formula 
3. A biologically acidified whey-adapted starter formula with 
probiotics 
Assignment was by a computer-generated randomisation table, and 
randomisation occurred separately at each hospital. Both investigators 
and participants were blinded to the formula assignments. Products 
were colour-coded and the formula composition did not appear on 
the tins. 
The probiotic strain selected was Bifidobacterium lactis, because 
of its resistance to gastric acidity and because safety and efficacy 
of this strain have been previously demonstrated when added to 
follow-up milk.16 However, this was the first study to evaluate the 
addition of probiotics to an acidified starter formula. 
At the time of enrolment, basic information regarding the pregnancy 
and delivery were recorded and study personnel measured the 
infants’ weight (to the nearest 10 g), length and head circumference 
(to the nearest millimetre) using standard equipment and techniques. 
Follow-up visits were scheduled for 14, 28, 42, 56, 91, 119 and 182 
days after enrolment for repeat measurements. 
After enrolment and randomisation to study formula, mothers 
received detailed instructions regarding the safe preparation of 
formula and were advised to feed on demand. It was stressed that 
only study formula should be given for the first four months. 
Infants were withdrawn from the study if the mother regularly gave 
more than one bottle per day of another milk formula, if the infant did 
not receive the study formula (due to the mother not being able to get 
supplies or illness in the infant) for more than seven consecutive days, 
or if significant amounts of foods other than formula were introduced 
before four months of age. Although withdrawn from the study, they 
were still offered the study formula until six months of age.
At study visits infants were examined by study personnel. Caregivers 
were interviewed regarding interim health status. A retrospective, 
two-day questionnaire obtained information on the amount of 
formula prepared, the amount remaining in the bottle after each feed, 
whether feeds were tolerated, and use of any other feeds. All unused 
formula was returned and correlated with reported consumption.  
Blood specimens were collected on all infants on days 42, 119 
and 182 by study physicians from a peripheral vein, if possible 
just before the next feed. On each occasion, the following were 
assayed: haemoglobin, albumin, total protein, blood urea, creatinine, 
quantitative amino acids (including tryptophan), ferritin, C-reactive 
protein, calcium, sodium, phosphate, potassium, chloride and 
glucose. Haemoglobin measurements were done by the Contract 
Research Laboratory of the National Health Laboratory Service and 
all biochemical assays were performed by the Centre Hospitalier 
Universitaire Vaudois, Laboratoire Central de Chimie Clinique in 
Lausanne, Switzerland. All biochemical test samples were collected 
in heparinised tubes and put on ice until centrifuged within one 
hour of collection. The supernatant plasma was stored in a -70°C 
refrigerator until shipment by a recognised international carrier. Blood 
was also collected on days 42 and 182 for HIV DNA Polymerase Chain 
Reaction (PCR) tests, performed by the National Institute for Virology 
in Johannesburg. All laboratories used were subject to internal and 
external quality control systems. 
The “acidification effect” was estimated by comparing the group 
receiving acidified formula without probiotics with the standard 
formula group, while the “probiotic effect” was estimated by 
comparing the acidified groups with and without probiotics.  
The sample size calculation was for non-inferiority of weight gain 
between enrolment and four months of age. The data collected 
by Nelson et al17 was used as a reference for the sample size 
calculation, with a mean growth of 28 g/day (sd = 5.7). A tolerance of 
3.9 g/day was accepted as non-inferior, and non-inferiority would be 
demonstrated if the 90% confidence interval for weight gain obtained 
with ANOVA controlling for gender and study site was above the level 
of -3.9 g/day. Using an alpha value of 0.05 and a power of 80%, 
it was calculated that 28 infants per formula group were required. 
Infants who were followed up for at least 119 days (four months) and 
were not HIV infected qualified for analysis, and it was estimated that 
30% of the infants would be lost to follow-up (20% due to dropout 
and 10% due to a late HIV-positive diagnosis). It was thus estimated 
that a total enrolment of 120 infants would be required. 
The growth parameters were calculated as mean growth velocities 
(i.e. increment per time interval). Statistical comparisons were made 
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by analysis of covariance (ANCOVA), controlling for gender and study 
site effects. Mean anthropometric Z-scores were calculated using 
Eurogrowth software,18 but this reference is only reliable after the 
first month of age.
The data from the two-day diaries were aggregated to visit level and 
tested per visit by ANCOVA. The statistical calculations were done 
using NCSS-2000 and SPSS-10.
Results
The study began in February 2000 and was completed in May 2002, 
with each hospital recruiting a similar number of subjects. During 
the course of the study, nevirapine prophylaxis against mother-to-
child transmission of HIV was gradually introduced to the hospitals in 
which the study was conducted, potentially increasing the number of 
infants not infected with HIV. However, loss to follow-up was higher 
than expected and thus an additional 11 infants were enrolled to 
ensure that 28 HIV-uninfected infants completed the study in each 
group, resulting in a total of 131 infants being enrolled.
Figure 1 illustrates the number of infants enrolled in each feeding 
group, the number that did not complete the study and those found 
subsequently to be HIV positive. Of the 33 infants (25%) who did not 
complete the study, 15 did not return at all after the initial enrolment 
visit. The most common reason for later loss to follow-up was non-
attendance and inability to trace the families (14 subjects). Other 
reasons included parental decision to withdraw (five subjects), non-
compliance with the study formula (four subjects), non-exclusive 
feeding with formula milk (six subjects), illness (five subjects), and 
other reasons (six subjects). More than one reason was applicable 
in some cases. There were no differences between the study groups 
in numbers of infants not completing the study, or completing but 
determined to be HIV positive. Of those who did not complete follow-
ups to four months (and considered lost to follow-up), four were 
found to be HIV positive. A total of 21 infants were lost to follow-
up prior to the first HIV PCR test at six weeks of age. Although 
some appointments were not attended at the scheduled dates, the 
mean age in days for all visits corresponded with the scheduled 
days except for the fourth visit, which took place at a mean age of 
57 rather than 56 days.  
Study subjects were generally of low socio-economic status (see 
Table I), with 62 (73%) having a total household income of less than 
R1 500 per month. There were no relevant demographic differences 
between the three feeding groups.
The effects of acidification and probiotics on anthropometric 
growth are presented in Table II. The group receiving the acidified 
formula did not differ in weight gain in comparison with the control 
group. The lower limit of the 90% confidence interval was equal to - 
1.4, which is above the level of -3.9 g/day, indicating that the 
acidification did not have a negative effect on weight gain. The probiotic 
effect, derived by comparing infants receiving the probiotic formula 
with those receiving the acidified formula without probiotics, showed 
that the infants receiving probiotics had an additional weight gain 
of 3.3 g/day, but this difference was not significant (p=0.06). 
Comparison of other anthropometric parameters showed a 
significant increase in head circumference for the probiotic group 
(p=0.04). Analysis of covariance showed a significant effect of gender 
on weight gain (p=0.002) but no significant effect of study site.  
The weight for age, length for age and head circumference for age 
Z-scores at each visit between 42 and 182 days are shown in Tables 
III, IV and V. No significant differences were seen between the groups 
at any of the time points.  




n = 29 n = 28 n = 28
Maternal age (years) mean (SD) 28.2 (5.1) 27.4 (5.6) 26.4 (3.9)
Maternal education mean (SD) 10.3 (2.0) 10.2 (2.3) 10.9 (2.1)
Household income < R1 500 pm 23 (79%) 20 (71%) 19 (68%)
Number (%) in formal housing 20 (69%) 16 (57%) 21 (75%)
Number (%) with piped water at 
their dwelling
27 (93%) 25 (89%) 27 (96%)
Number (%) with flush toilet 29 (100%) 24 (86%) 25 (89%)
Number (%) with electric stove 24 (83%) 22 (79%) 22 (79%)
Number (%) with fridge 18 (62%) 16 (57%) 15 (54%)
Number (%) where parent was 
caregiver
26 (90%) 27 (96%) 27 (96%)
Number (%) of male infants 17 (59%) 15 (54%) 12 (43%)
Birth weight (grams) mean (SD) 3 206 (350) 3 144 (361) 3 180 (396)
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Figure 1: Flow diagram of participants
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The amount of milk formula given in the two days prior to each visit 
was not significantly different between the groups, except for visit 
5 (91 days), when more control formula was consumed than either of 
the acidified formulas. Up to visit 6 (119 days) there were few cases 
of giving additional foods: 9 of 174 (5%) assessment days in the 
acidified plus probiotic group, 5 of 168 (3%) in the acidified formula 
group, and 9 of 168 (5%) in the control formula group.  
Tolerance of feeds was assessed by subjective maternal assessment 
of the number of stools, number of episodes of spitting up, the 
number of vomits per day, the frequency of hard or loose stools, 
the frequency of flatulence, and the proportion of the time when the 
infant was restless on the two days preceding each of the first six 
visits. There were no significant differences in these parameters.
A total of 17 infants required hospital admission during the course 
of the study, five of whom failed to complete the study. There 
were five cases of proven or suspected septicaemia, five cases of 
gastroenteritis and dehydration (one of which was also considered 
to be septicaemic) and three cases of bronchopneumonia or 
bronchiolitis. Of these seventeen cases, five were in HIV-infected 
infants, three in infants of unknown HIV status, and a further nine 
among the 85 infants who completed the study. There was no 
significant difference in rates of serious illness between the study 
groups: Seven cases were in infants assigned to the formula with 
probiotics, four in infants assigned to the acidified formula without 
probiotics, and six in those assigned to the control formula. The 
data was also analysed for gastrointestinal symptoms that did 
not require hospital admission. Episodes of vomiting, diarrhoea or 
gastroenteritis were found in eight of the infants assigned to each of 
the acidified formula groups and in eleven of those assigned to the 
control formula. However, these differences were not significant.
The laboratory results were compared to assess the acidification 
effect and the probiotic effect using a regression analysis (ANCOVA). 
Compared to infants taking the control formula, those taking the 
acidified formulas had significantly higher serum levels of arginine, 
citrulline and glycine, and lower levels of lysine. Those taking 
the probiotic formula had significantly lower levels of proline and 
tyrosine. The magnitude of all these differences was small and not 
considered clinically significant. With respect to the other laboratory 
measurements, the infants receiving the control formula had 
significantly higher levels of chloride and glucose, but the mean 
differences were small and not considered clinically significant. 
Infants receiving the control formula also had significantly higher 
levels of serum ferritin without higher C-reactive protein levels.
Discussion
The primary objective of the study was to assess whether weight 
gain of infants receiving acidified formula, with or without probiotics, 
was inferior to that of infants being fed control formula. The data 
showed no significant effects on growth parameters when using an 
acidified milk formula. However, the effect of probiotics approached 
significance for greater weight gain (p=0.06) and was significant for 
greater gain in head circumference. Since the study was powered as 
a non-inferiority study, it may not have succeeded in demonstrating 
increased weight gain using probiotics. Although no statistical 
differences were seen in Tables III, IV and V, the trends seen in mean 
Z-scores up to 119 days for weight and head circumference also 





n Mean (SD) n Mean (SD)
Weight gain (g/day)
Acidified + probiotic 17 37.6 (7.2) 12 34.3 (6.6) a3.3 (1.7) 0.06
Acidified 15 35.6 (5.5) 13 29.2 (7.2) b1.4 (1.7) 0.40
Control 12 32.8 (4.1) 16 29.0 (6.3)
Length gain (mm/day)
Acidified + probiotic 17 1.12 (0.16) 12 1.04 (0.12) a0.04 (0.04) 0.24
Acidified 15 1.17 (0.12) 13 1.0 (0.15) b0.03 (0.04) 0.36
Control 12 1.12 (0.16) 16 1.0 (0.13)
Head circumference gain (mm/day)
Acidified + probiotic 17 1.56 (0.52) 12 1.53 (0.52) a0.05 (0.03) 0.04
Acidified 15 1.44 (0.49) 13 1.30 (0.51) b0.001 (0.02) 0.96
Control 12 1.26 (0.25) 16 1.31 (0.55)
a Probiotic effect (acidified + probiotic versus acidified)
b Acidification effect (acidified versus control)
c p-value of analysis of variance controlling for gender and study site 
Table III: Weight for age Z-scores of study subjects by feeding group
AGE* ACIDIFIED AND PROBIOTIC ACIDIFIED CONTROL
6 weeks 0.22 ± 0.94 -0.08 ± 1.05 -0.03 ± 1.13
2 months 0.40 ± 0.94 0.23 ± 0.98 0.12 ± 0.98
3 months 0.80 ± 0.94 0.36 ± 1.16 0.21 ± 0.99
4 months 1.02 ± 1.07 0.41 ± 1.02 0.20 ± 1.01
6 months 0.70 ± 1.25 0.10 ± 1.02 0.03 ± 1.04
No significant intergroup differences were found.
*The ages correspond to the visits at 42, 56, 91,119 and 182 days (see text).
Table IV: Length for age Z-scores of study subjects by feeding group
AGE* ACIDIFIED AND PROBIOTIC ACIDIFIED CONTROL
6 weeks -0.21 ± 0.80 -0.40 ± 0.96 -0.56 ± 1.14
2 months -0.38 ± 0.89 -0.42 ± 0.95 -0.32 ± 0.91
3 months 0.04 ± 0.78 -0.18 ± 1.01 -0.14 ± 0.96
4 months 0.05 ± 0.89 -0.33 ± 1.08 -0.60 ± 0.92
6 months -0.03 ± 1.07 0.28 ± 1.21 -0.57± 0.96
No significant intergroup differences were found.
*The ages correspond to the visits at 42, 56, 91,119 and 182 days (see text). 
Table V: Head circumference for age Z-scores of study subjects by feeding group
AGE* ACIDIFIED AND PROBIOTIC ACIDIFIED CONTROL
6 weeks 0.54 ± 0.82 0.67 ± 0.95 0.52 ± 0.95
2 months 0.73 ± 0.75 0.78 ± 1.00 0.67 ±1.14
3 months 0.80 ± 0.96 0.68 ± 0.86 0.81 ± 0.88
4 months 1.02 ± 0.77 0.74 ± 1.09 0.85 ± 1.05
6 months 0.60 ± 0.78 0.63 ± 1.34 0.62 ± 1.14
No significant intergroup differences were found.
*The ages correspond to the visits at 42, 56, 91,119 and 182 days (see text). 
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suggested an advantage for the group who received the acidified 
formula with probiotics. The decrease in mean Z-scores between 
119 and 182 days corresponded with the introduction of foods other 
than milk.
The greater gain in head circumference and the trend towards greater 
weight gain noted in infants receiving formula with probiotics were 
not related to greater energy or protein intake. The formulas had 
the same caloric density, and there was no greater intake of study 
formula or other nutrients. In fact, at visit 5 (mean age 91 days) the 
history of milk intake was significantly less in the infants randomised 
to either of the acidified formulas, although this may have been a 
chance finding since multiple comparisons were performed. Other 
factors that may affect growth are socio-economic status and 
gender. There were no differences in socio-economic status detected 
between the study groups. There were somewhat fewer male infants 
in the control group and, although it is known that male infants grow 
faster than females, in this study the trend toward improved growth 
in infants receiving the formula with probiotics was present in both 
male and female infants. In addition, the overall effect of formula 
persisted after controlling for gender in a multivariate analysis.    
Probiotics may have functional effects on the gastrointestinal tract 
that improve digestion or absorption of the energy content of the 
formula. Previously demonstrated functional effects of specific 
probiotics include reduced gut permeability and enhanced local 
intestinal and systemic immunity.19
There was a higher than expected rate of loss to follow-up, with 75% 
of subjects followed to completion. Losses to follow-up were evenly 
spread across the three study groups and therefore are unlikely to 
represent a lack of tolerance of any specific milk. Almost half of the 
losses to follow-up occurred early, with failure to return for the first 
follow-up visit. Several study subjects mentioned a concern that the 
use of colour-coded tins may draw attention to their HIV-positive 
status, as the community increasingly identifies non-breast-feeding 
with HIV. Some of the loss to follow-up may be due to HIV-related 
illnesses in women or infants. In addition, many women come from 
outside of Johannesburg to deliver their infants and then return to 
their homes soon thereafter. It is probable that some of those lost to 
follow up were in this category.
Although some infants who were admitted with gastroenteritis and 
dehydration were noted to be acidotic and concern was expressed 
during the blinded phase of the study regarding the tolerance of 
young infants of acidified formulas with respect to acid-base balance, 
when the code was broken there was no evidence of any differences 
in this regard between the formula groups. The differences shown 
between the study groups with respect to some of the biochemical 
parameters were considered small and not clinically significant.  
Conclusions
In this controlled trial of infants fed acidified formulas with and 
without added probiotics compared to a standard infant formula, 
there was good growth of infants in all study groups. Growth in head 
circumference was greater in infants receiving formula containing 
probiotics compared to formula that was only acidified and there was 
a trend towards increased weight gain. There were no differences in 
morbidity between infants in the three study groups, and all types of 
study milk were well tolerated. Further studies are required to define 
the separate effects of acidification and probiotics.
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